Short Bowel Syndrome Drugs Market Size And Share

Report Code : TIPRE00021601
Category : Life Sciences

No. of Pages : 150

Buy Now

Marktgröße und Marktanteil von Medikamenten gegen Kurzdarmsyndrom bis 2025 – 2031

Buy Now

Short Bowel Syndrome Drugs Market Report Analysis

Short Bowel Syndrome Drugs Market

CAGR (2023 - 2031)
XX%
Market Size 2023
US$ XX million
Market Size 2031
US$ XX Million

Report Coverage

Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope

Key future trends
Detailed PEST/Porter’s Five Forces and SWOT analysis

Industry landscape and competition analysis & recent developments
Detailed company profiles

Global and regional market analysis covering key market trends, major players, regulations, and recent market developments

Key Players

Takeda Pharmaceutical Company Limited
Pfizer Inc.
Novartis AG
Mylan N.V.
AstraZeneca Plc
Sancilio Pharmaceuticals Company, Inc.
Nutrinia Ltd
Ardelyx, Inc.
Merck and Co., Inc

Regional Overview

Nordamerika
Europa
Asien-Pazifik
Süd- und Mittelamerika
Naher Osten und Afrika

Market Segmentation

By Medikamentenklasse

Glucagon-ähnliches Peptid
Mittel gegen Durchfall
Protonenpumpenhemmer
Histaminblocker
Wachstumshormon
andere

By Vertriebskanal

Krankenhaus- und Einzelhandelsapotheken
Online-Vertrieb

By Geographie

Nordamerika
Europa
Asien-Pazifik
Süd- und Mittelamerika